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ABSTRACT:
Autophagy inhibition is a novel cancer therapeutic strategy in the early stages of 
clinical trial testing.  The initial rationale for using autophagy inhibition was generated 
by research revealing that autophagy is upregulated in response to external stresses, 
including chemotherapy and radiotherapy. Combining autophagy inhibition with 
agents that induce autophagy as a pro-survival response may therefore increase their 
therapeutic efficacy. Recent research has shown that some cancer cells, particularly 
those driven by the K-Ras oncogene, also depend on elevated levels of autophagy 
for survival even in the absence of external stressors. In multiple in vitro as well 
as in vivo systems, oncogenic Ras-mediated transformation and tumor growth are 
dependent on autophagy to evade metabolic stress and cell death. These studies 
have subsequently led to further early phase clinical testing whether autophagy 
inhibition is a viable and effective strategy for targeting Ras-driven tumors. Even 
before the clinical results are available from these ongoing clinical trials, much 
work remains to optimally develop the approach of autophagy inhibition clinically; 
most notably reliably detecting levels of autophagy in human tumor samples, 
pharmacodynamics of currently available autophagy inhibitors (chloroquine and the 
derivative hydroxychloroquine), and new target identification and drug development.
Autophagy inhibition is at the forefront of cancer 
therapy, with approximately 20 ongoing clinical trials in 
multiple varied cancers employing this strategy as either 
monotherapy or in combination with other agents [1]. 
The initial interest in autophagy inhibition as a cancer 
therapy was generated by research revealing that some 
cancers depend on autophagy for survival during external 
stresses such as hypoxia, chemotherapy, or radiotherapy 
[2]. A new rationale for targeting autophagy has recently 
been elucidated by our group as well as several others 
showing that elevated levels of autophagy are required 
for cancer cells to evade lethal metabolic stress and 
to maintain metabolic homeostasis, particularly in 
tumorigenesis driven by the K-Ras oncogene [3-6]. Here 
we will examine the evidence for autophagy addiction 
as a survival strategy in Ras oncogene-mediated cancers 
and how current and future therapeutic strategies aim to 
exploit this addiction. 
Macroautophagy (referred to hereafter as autophagy) 
is a conserved, regulated catabolic cellular pathway that 
degrades cellular organelles and other macromolecules 
[7-8].  The  process  involves  both  non-specific  and 
targeted sequestration of cargo in a double membrane 
vesicle (autophagosome) that fuses to a lysosome 
(autolysosome), allowing for degradation of cargo and 
recycling of bioenergetic metabolites [9]. Autophagy has 
been shown to play a role in diverse disease processes 
including neurodegeneration, atherosclerosis, and cancer 
[10]. Initial research demonstrated that autophagy may 
function as a tumor suppressor with defects in autophagy 
predisposing to tumor development in certain mouse 
models [12]. Conversely, autophagy has also been shown 
to have pro-tumorigenic roles in promoting therapeutic 
resistance to cytotoxic chemotherapy as well as survival 
under stresses such as hypoxia [2]. It is likely that the 
function of autophagy in cancer is dynamic with both 
protumorigenic and tumor suppressive roles which depend 
on tumor stage, cellular context and tissue of origin Oncotarget 2011; 2:   1302 - 1306 1303 www.impactjournals.com/oncotarget
[11]. Recently, several groups, including our own, have 
investigated whether autophagy plays a pro-tumorigenic 
role in oncogene mediated malignant transformation and 
subsequent tumor maintenance. Collectively the data 
demonstrate that in the setting of cellular transformation, 
oncogenic Ras expression leads to an increase in autophagy 
and that this upregulation is necessary for survival and for 
transformation. These findings suggest Ras-driven tumors 
may be particularly sensitive to autophagy inhibition. 
Our group has examined the correlation of autophagy 
induction and oncogenic K-Ras both directly and indirectly 
[3]. While exploring the notorious treatment resistance of 
pancreatic ductal carcinoma (PDAC), a tumor that nearly 
universally possesses K-Ras mutations, we noted that 
all human-derived PDAC cell lines examined showed 
elevated basal autophagy. Autophagy was also elevated in 
81% of primary PDAC tumor samples as well as in high-
grade pancreatic intraepithelial neoplasms (PanINs), but 
was not elevated in normal pancreatic ductal epithelium or 
low-grade PanIN. Pharmacologic inhibition of autophagy 
with chloroquine (an antimalarial drug that inhibits 
autophagosomal degradation by interfering with lysosome 
pH) or genetic inhibition of autophagy in multiple 
PDAC cell lines attenuated growth and tumorigenicity 
in vitro as well as in vivo in tumor xenograft mouse 
models. Furthermore, chloroquine (CQ) treatment of 
an autochthonous K-Ras-driven genetically engineered 
PDAC mouse model led to a significant increase in survival 
as a monotherapy. This model has been shown by several 
groups to be highly refractory to conventional treatments 
as well as targeted agents [13]. Mechanistically, our 
work shows that autophagy is critical for proper cellular 
metabolism in these tumors. In particular, autophagy 
inhibition  results  in  a  significant  decrease  in  oxidative 
phosphorylation. Together, our data provides compelling 
pre-clinical evidence supporting the strategy of targeting 
autophagy in the setting of an oncogenic K-Ras driven 
tumor. Coincident with our studies, several other groups 
have explored the relationship between oncogenic Ras-
induced transformation and autophagy, further building 
the case for targeting autophagy addiction, not just in 
pancreatic cancers but in other Ras-driven tumors as well 
(see below).
Three recent studies have shown that autophagy 
is essential for oncogenic Ras-induced malignant cell 
transformation [4-6]. The White lab explored the functional 
rationale for autophagy induction in Ras-transformed 
cells and again demonstrates a critical metabolic function 
for autophagy. In a series of experiments, they show that 
oncogenic H-Ras and K-Ras both upregulate autophagy 
which supports cell survival and transformation primarily 
through maintenance of mitochondrial metabolic 
function and energy levels. The authors primarily used 
immortalized, non-tumorigenic baby mouse kidney 
epithelial cells in which they expressed oncogenic H-Ras 
or K-Ras to levels comparable to human cancer cell lines. 
Genetic inhibition of autophagy decreased cell survival 
during starvation and abrogated tumorigenesis in mice. 
The authors confirmed the relevance of their results to 
human cancer by showing that a number of human cancer 
cell lines with endogenous oncogenic Ras mutations, 
including pancreatic, bladder, and lung cancer cell lines, 
had a significant increase in the level of basal autophagy. 
Pharmacologic and genetic inhibition of autophagy in 
these cell lines revealed that a number were dependent 
on autophagy for cell growth, survival and proliferation. 
Consistent with our studies, the authors showed a 
decrease in oxidative phosphorylation as well a decrease 
in tricarboxylic acid (TCA) cycle intermediates. However, 
unlike in the case of our findings in pancreatic cancer, they 
demonstrate a buildup of damaged mitochondria due to the 
inhibition of mitochondrial autophagy (mitophagy). They 
concluded that oncogenic Ras imposes a metabolic insult 
on cells that depletes energy sources thereby making the 
cells dependent on autophagy to preserve mitochondrial 
function for energy production and perhaps directly 
provide catabolically derived metabolic substrates. 
Another study explored the mechanistic link between 
oncogenic Ras expression and autophagy induction. Kim et 
al. used the spontaneously immortalized, non-transformed 
human breast epithelial cell line, MCF10A, and expressed 
constitutively active oncogenic K-Ras [5]. Elevated 
levels of autophagy were necessary for transformation 
of these cells, as pharmacologic and genetic inhibition of 
autophagy abrogated in vitro transformation and tumor 
growth in immunocompromised mice. The authors also 
provided evidence that oncogenic K-Ras expression 
upregulated autophagy via a mechanism involving ROS, 
p38 MAPK, and JNK activation. These conclusions 
warrant further exploration in complementary in vitro 
as well as in vivo systems, as elucidating this link could 
suggest additional strategies for therapeutic intervention 
to prevent the continued activation of autophagy in K-Ras 
driven tumors.
A study from the Debnath lab used oncogenic 
H-Ras expressing cell lines as well as several cell lines 
with endogenous K-Ras mutations to show that basal 
autophagy is elevated in oncogenic Ras expressing cells 
grown in non-adherent conditions, and cells deficient in 
autophagy exhibit decreased cell proliferation and soft 
agar formation [6]. Given the reliance on autophagy for 
cell proliferation, the authors tested whether autophagy 
was involved in cellular metabolism. In autophagy 
deficient mouse embryonic fibroblasts (MEF) expressing 
oncogenic Ras, there was a decrease in both glucose 
uptake  and  in  glycolytic  flux  suggesting  dependence 
on autophagy for glycolytic capacity. Consistent with 
other studies, including our own, autophagy appears to 
be necessary for metabolism in Ras transformed cells. 
However, in this case glycolysis appears to be critically 
affected. These differences may reflect specifics of the 
experimental system, such as the acute inhibition of Oncotarget 2011; 2:   1302 - 1306 1304 www.impactjournals.com/oncotarget
autophagy in a chronically transformed tumor cell with 
CQ or RNAi versus transforming a chronically autophagy 
incompetent cell, such as ATG5 null MEFs. The general 
theme, however, is that autophagy induction supports 
cellular metabolism in the context of metabolic stress 
induced by oncogenic Ras transformation (Figure 1). 
The particulars with regards to cell system and tumor 
type deserve attention in the form of comprehensive 
metabolomics studies. Such studies may further elucidate 
targets for pharmacologic intervention.
While the majority of studies have shown that 
oncogenic Ras results in elevated autophagy and this 
is critical for tumorigenesis, Elgendy et al. have shown 
that in some contexts oncogenic Ras expression and 
autophagy activation may potentially lead to cell death 
[14]. In their experimental system, the acute induction of 
oncogenic H-Ras expression causes cells to undergo an 
irreversible proliferative arrest and marked reduction in 
ability to form colonies. The authors showed that these 
cells  have  an  increase  in  autophagic  flux,  but  genetic 
inhibition of autophagy in this case decreased Ras-
induced death. The authors concluded that oncogenic Ras 
expression leads to an autophagic cell death, which could 
act to limit transformation after induction of deregulated 
Ras signals. There are several key aspects of the study that 
could explain the differences with the studies that have 
shown that autophagy is necessary for Ras transformation. 
The use of a tetracycline inducible H-Ras G12V can cause 
an acute over-expression of H-Ras, which is in contrast 
to stable cell lines or endogenous mutations in tumor cell 
lines. Additionally, HOSE cells are not transformed by 
oncogenic Ras, unlike the MEFs, MCF10A, or kidney 
epithelial cells. Thus, while Ras activates autophagy in 
these cells, the ultimate cellular fate by autophagy may 
depend on the cellular consequence of oncogenic Ras 
expression. Lastly, it is important to note that the role 
of autophagy in promoting cellular death in mammalian 
systems is still somewhat controversial [15] and recent 
studies suggest autophagic cell death may not be a 
generalized phenomenon [16]. 
Given the pre-clinical evidence suggesting 
autophagy acts as a survival mechanism in response to 
chemotherapy, multiple clinical trials have been initiated, 
most studying combinations of autophagy inhibition 
with both traditional chemotherapy as well as targeted 
agents. Based on our pre-clinical evidence suggesting a 
pro-survival role for autophagy in pancreatic cancer [3], 
we have opened multiple clinical trials at our institution 
for patients with pancreatic cancer. The evidence 
presented above for the pro-survival role of autophagy in 
oncogenic-Ras transformed cancer cell lines suggests that 
other Ras-driven tumors may be particularly sensitive to 
autophagy inhibition as well. Additionally, the data also 
suggests that tumors with elevated basal autophagy will 
be appropriate candidates for anti-autophagy therapies as 
well. Determining the relevant tumor type and optimal 
therapeutic combinations will be critical and a significant 
amount of pre-clinical and clinical work is currently 
ongoing to answer these questions. 
Even before the clinical results are available from 
ongoing clinical trials testing autophagy inhibition in 
cancer, much work remains to optimally develop the 
approach of autophagy inhibition clinically (Figure 2). 
First, our methods for measuring basal autophagy or 
whether autophagy is inhibited in patient samples, by 
IHC and western blotting for autophagic markers, are 
limited and of unproven utility in human patients. The 
pharmacodynamic studies in these ongoing clinical 
trials as well as in pre-clinical mouse models will be 
necessary to determine whether our current drugs as well 
as future compounds are achieving effective autophagy 
inhibition before we can conclusively determine the 
success or failure of autophagy inhibition as a therapeutic 
strategy. At present, all human trials exploring autophagy 
inhibition as a therapeutic strategy are using CQ or the 
derivative hydroxychloroquine given the long track 
record of safety in human patients. However, whether CQ 
and its derivatives represent the most efficacious methods 
for inhibiting autophagy is debatable. The high doses of 
CQ required to achieve tumor inhibition are obtainable 
in humans, but are not ideal due to the pharmacology of 
the drug [17-18]. Mechanistically, CQ blocks lysosome 
acidification,  which  is  not  specific  to  autophagy,  but 
may have other potentially beneficial anti-tumor effects 
in addition to autophagy inhibition. There are multiple 
earlier steps in the autophagy pathway that may represent 
suitable targets, including the kinases Vps34, a class III 
PI3K, and ULK1/2, another family of kinases involved in 
the early activation of autophagy. Indeed, a recent study 
Figure 1: Ras oncogene-induced transformation and 
tumorigenesis depends on autophagy induction to 
evade potentially lethal metabolic stress. The green dots 
in the orange and red cells represent autophagic puncta.Oncotarget 2011; 2:   1302 - 1306 1305 www.impactjournals.com/oncotarget
showed that a small molecule, Spautin-1, promoted the 
degradation of Vps34 by inhibiting two ubiquitin-specific 
proteases USP10 and USP13 that regulate the stability of 
the Vps34 complex [19]. By this mechanism, Spautin-1 
increased cancer cell death in the setting of nutrient 
deprivation when autophagy would normally act as a 
survival mechanism in these metabolically stressed cells. 
This  compound  and  strategy  would  require  significant 
further pre-clinical testing before it could be employed 
in humans. Given the interest in autophagy inhibition, 
many other research groups are interested in developing 
improved autophagy inhibitors for cancer treatment and 
likewise pharmaceutical companies have also focused 
their attention on autophagy inhibition as a promising 
therapeutic avenue [20]. 
In conclusion, the studies reviewed here show that in 
multiple in vitro as well as in vivo systems, oncogenic Ras-
mediated transformation and tumor growth are dependent 
on autophagy to evade metabolic stress and cell death. 
Autophagy inhibition is still in the early stages as a cancer 
therapeutic strategy but future work promises to determine 
whether this represents a viable and effective strategy for 
targeting Ras-driven tumors. While the preclinical data in 
mutant Ras tumors, in particular pancreatic cancers, is the 
most developed, there are likely to be other tumor types 
and driving genetic events that also exhibit autophagy 
addiction. Future work from multiple laboratories as well 
as results from ongoing clinical trials will allow us to 
answer these and other critical questions.
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Figure 2: Future directions and challenges in autophagy inhibition. A) Large scale screening of human tumor samples and 
cell lines, both oncogenic Ras-driven and otherwise, for elevated basal autophagy will identify a subset of tumors that may be particularly 
sensitive to autophagy inhibition as a therapeutic strategy. Method development will be required to translate this aim given the limited 
utility of current methods for examining human tumor samples for basal autophagy. B) Pre-clinical testing of autophagy inhibition as a 
therapeutic strategy in autophagy dependent tumors will lead to future clinical trials. Pre-clinical model development, pharmacodynamics 
of current autophagy inhibitory drugs, new target identification, and new inhibitor development are all important challenges facing the field 
of researchers investigating autophagy inhibition.  C) Ongoing and future human clinical trials employing autophagy inhibition either as 
monotherapy or in combination with chemotherapy or targeted therapy will test the utility of autophagy inhibition as a cancer therapeutic 
strategy.Oncotarget 2011; 2:   1302 - 1306 1306 www.impactjournals.com/oncotarget
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